DOCSLIB.ORG

Long-Lasting Correction of in Vivo LTP and Cognitive Deficits of Mice

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Long-Lasting Correction of in Vivo LTP and Cognitive Deficits of Mice Long-lasting correction of in vivo LTP and cognitive deficits of mice modelling Down syndrome with an α5-selective GABAA inverse agonist Arnaud Duchon, Agnès Gruart, Christelle Albac, Benoît Delatour, Javier Zorrilla de San Martin, José María Delgado-garcía, Yann Hérault, Marie-claude Potier To cite this version: Arnaud Duchon, Agnès Gruart, Christelle Albac, Benoît Delatour, Javier Zorrilla de San Martin, et al.. Long-lasting correction of in vivo LTP and cognitive deficits of mice modelling Down syn- drome with an α5-selective GABAA inverse agonist. British Journal of Pharmacology, Wiley, 2019, 10.1111/bph.14903. hal-02388584 HAL Id: hal-02388584 https://hal.archives-ouvertes.fr/hal-02388584 Submitted on 25 May 2021 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Received: 9 May 2019 Revised: 12 September 2019 Accepted: 15 September 2019 DOI: 10.1111/bph.14903 RESEARCH PAPER Long-lasting correction of in vivo LTP and cognitive deficits of mice modelling Down syndrome with an α5-selective GABAA inverse agonist Arnaud Duchon1,2,3,4 | Agnès Gruart5 | Christelle Albac6,7,8,9 | Benoît Delatour6,7,8,9 | Javier Zorrilla de San Martin6,7,8,9 | José María Delgado-García5 | Yann Hérault1,2,3,4 | Marie-Claude Potier6,7,8,9 1Translational Medicine and Neurogenetics, Institut de Génétique et de Biologie Background and Purpose: Excessive GABAergic inhibition contributes to cognitive Moléculaire et Cellulaire, Illkirch, France dysfunctions in Down syndrome (DS). Selective negative allosteric modulators 2Centre National de la Recherche Scientifique, α α α UMR7104, Illkirch, France (NAMs) of 5-containing GABAA receptors such as the 5 inverse agonist ( 5IA) 3Institut National de la Santé et de la restore learning and memory deficits in Ts65Dn mice, a model of DS. In this study we Recherche Médicale, U1258, Illkirch, France have assessed the long-lasting effects of α5IA on in vivo LTP and behaviour in 4Neuropôle, Université de Strasbourg, Illkirch, Ts65Dn mice. France 5División de Neurociencias, Universidad Pablo Experimental Approach: We made in vivo LTP recordings for six consecutive days in de Olavide, Seville, Spain freely moving Ts65Dn mice and their wild-type littermates, treated with vehicle or 6 Institut du Cerveau et de la Moelle épinière, α5IA. In parallel, Ts65Dn mice were assessed by various learning and memory tests Hôpital de la Pitié-Salpêtrière, Paris, France 7Institut National de la Santé et de la (Y maze, Morris water maze, or the novel object recognition) for up to 7 days, Recherche Médicale, U1127, Hôpital de la following one single injection of α5IA or vehicle. Pitié-Salpêtrière, Paris, France Key Results: LTP was not evoked in vivo in Ts65Dn mice at hippocampal 8Centre National de la Recherche Scientifique, UMR7225, Hôpital de la Pitié-Salpêtrière, CA3-CA1 synapses. However, this deficit was sustainably reversed for at least six Paris, France consecutive days following a single injection of α5IA. This long-lasting effect of 9Sorbonne Université, Hôpital de la Pitié- α5IA was also observed when assessing working and long-term memory deficits in Salpêtrière, Paris, France Ts65Dn mice. Correspondence Conclusion and Implications: We show for the first time in vivo LTP deficits in Marie-Claude Potier, ICM Institut du Cerveau et de la Moelle épinière, CNRS UMR7225, Ts65Dn mice. These deficits were restored for at least 6 days following acute INSERM U1127, Sorbonne Université, Hôpital treatment with α5IA and might be the substrate for the long-lasting pharmacological de la Pitié-Salpêtrière, Paris, France. Email: [email protected] effects of α5IA on spatial working and long-term recognition and spatial memory tasks. Our results demonstrate the relevance of negative allosteric modulators of Funding information Fondation Jérôme Lejeune; Investissements α5-containing GABAA receptors to the treatment of cognitive deficits associated d'avenir, Grant/Award Numbers: ANR- with DS. 10-INBS-07 PHENOMIN, ANR-10-LABX- 0030-INRT, ANR-10-IDEX-0002-02, ANR- Abbreviations: α5IA, 1-methyl-4-({[3-(5-methyl-1,2-oxazol-3-yl)-[1,2,4]triazolo[3,4-a]phthalazin-6-yl]oxy}methyl)-1H-1,2,3-triazole (α5 inverse agonist); DS, Down syndrome; fEPSP, field EPSP; HFS, high frequency stimulation; IEG, immediate early gene; MWM, Morris water maze; NAM, negative allosteric modulator; NOR, novel object recognition. Yann Hérault and Marie-Claude Potier have equal contribution. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. © 2019 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society 1106 wileyonlinelibrary.com/journal/bph Br J Pharmacol. 2020;177:1106–1118. DUCHON ET AL. 1107 10-IAIHU-06; Agence Nationale de la Recherche; Junta de Andalucía, Grant/Award Numbers: BIO122, CVI 2487, P07-CVI-02686; MINECO, Grant/Award Numbers: BFU2011-29089, BFU2011-29286 1 | INTRODUCTION What is already known Down syndrome (DS) is the consequence of a third complete or partial • The α5 inverse agonist (α5IA) reverses cognitive deficits copy of human chromosome 21 (Antonarakis, 2017; Antonarakis, Lyle, in Ts65Dn mice modelling Down syndrome. Dermitzakis, Reymond, & Deutsch, 2004; Lejeune, Gautier, & Turpin, 1959). It is associated with physical abnormalities including character- What does this study add istic facial features and cognitive deficits producing variable impair- • α5IA produces long-lasting pharmacological effects by ments in intellectual functioning. In recent years, beside cognitive sustainably restoring in vivo LTP in Ts65Dn mice. therapies that have proven to be useful for improving deficits in DS, active research has identified possible pharmacological treatments in What is the clinical significance mouse models (Martinez-Cue, Delatour, & Potier, 2014; Ruparelia, • These results highlight the interest of α5IA for treating Pearn, & Mobley, 2012; Stagni, Giacomini, Guidi, Ciani, & Bartesaghi, cognitive deficits in Down syndrome. 2015). Several mouse models have been extremely useful for deci- phering the mechanisms involved in cognitive defects in DS and for the design of preclinical studies (Herault et al., 2017; Sheppard, Wise- man, Ruparelia, Tybulewicz, & Fisher, 2012). The most widely used mouse model is the Ts(1716)65Dn, Ts65Dn mouse (Reeves et al., 1995). These mice, carrying a partial Mmu16 trisomy for 122 genes, α5IA could produce in parallel a long-lasting effect on cognition and reproduce DS memory defects and show deficits in LTP on hippocam- found that indeed a single dose of α5IA was able to reverse learning pal slices, that are reversed by non-selective antagonists of GABAA and memory deficits up to 7 days after injection. We propose that a receptors (Kleschevnikov et al., 2004). In addition, GABAA antagonists single dose of α5IA is sufficient to induce a profound and long-lasting restore cognitive impairments in Ts65Dn mice (Colas et al., 2013; remodelling of neuronal circuits involved in the cognitive functions Colas, Chuluun, Garner, & Heller, 2017; Fernandez et al., 2007; Rueda, that are affected in DS. Florez, & Cue, 2008). Previously, we demonstrated that a single dose of the α5 inverse agonist (α5IA), a selective negative allosteric modulator 2 | METHODS (NAM) of GABAA receptors containing the α5 subunit (Dawson et al., 2006), was able to rescue learning and memory deficits and 2.1 | Mouse lines to promote immediate early gene (IEG) synthesis in the hippocam- pus of Ts65Dn mice (Braudeau et al., 2011; Braudeau et al., 2011). All animal care and experimental procedures complied with European Subsequently, another inverse agonist of α5-containing GABAA Union Council (2010/63/EU), the French Ministry of Agriculture (87 receptors, RO4938581, was shown to correct cognitive deficits of 848), and Spanish (BOE 252/34367-91, 2005) guidelines for the use Ts65Dn mice and to restore LTP in hippocampal slices after of laboratory animals in chronic electrophysiological and behavioural long-term treatment (Martinez-Cue et al., 2013). The same study studies. In addition, French National Ethics Committees approved all showed that RO4938581 improved density of GABAergic synaptic experimental protocols under the accreditation numbers APAFIS3152 markers in the molecular layer of the hippocampus of Ts65Dn mice. and 4670. Marie-Claude Potier and Yann Hérault received official The GABAA receptors containing the α5 subunit are involved in cog- authorization from the French Ministry of Agriculture to carry out nitive processes of learning and memory and are preferentially research and experiments on animals (authorization numbers 75-2138 expressed in the hippocampus (Prut et al., 2010; Wisden, Laurie, and 67-369, respectively). Consistent with these guidelines, statistical Monyer, & Seeburg, 1992). analyses were used to minimize the number of animals used, within Although NAMs of α5-containing GABAA receptors reversed LTP the constraints of necessary
Load more

Recommended publications
  • 42711 IPEG Programmaboekje
    19 th Biennial Conference 19th Biennial Conference October 26th – 30th 2016 October 26 Nijmegen, the Netherlands th – 30 th 2016 Nijmegen, the Netherlands 2016 Nijmegen, 42711 IPEG programmaboekje omslag.indd 1 06-10-16 17:52 The “International Pharmaco-EEG Society, Association for Electrophysiological Brain Research in Preclinical and Clinical Pharmacology and Related Fields” (IPEG) is a non-profit organization, established in 1980 and composed of scientists and researchers actively involved in electrophysiological brain research in preclinical and clinical pharmacology, neurotoxicology and related areas of interest. my.thesis nl for the design of your Thesis & to show your Thesis 42711 IPEG programmaboekje omslag.indd 2 06-10-16 17:52 IPEG 2016 in Nijmegen | 1 Welcome to Nijmegen, dear attendants of the 19th IPEG meeting. Nijmegen, a 2000 year old city; Nijmegen, a Roman and a medieval city; Nijmegen, the home town of the first catholic university funded by the Faithfull to improve education of a suppressed part of the Netherlands; Nijmegen, the city that heavily suffered in WWII; Nijmegen, the home town of the Donders Institute. Nijmegen, as we hope and trust, your home town for the upcoming IPEG meeting. As you all know, electrophysiological brain research has a long tradition going back as far as 1875 when the first report on the animal electroencephalogram (EEG) was published by Caton. The often forgotten Polish physiologist Adolf Beck was also a EEG pioneer many years before Hans Berger’s initial reports. Beck recorded electrical potentials in several brain areas evoked by peripheral sensory stimuli. Using this technique, Beck localised various centres in the brain of several animal species and described desynchronization in electrical brain potentials.
    [Show full text]
  • 19Th Biennial IPEG Meeting Nijmegen, the Netherlands
    Neuropsychiatric Electrophysiology 2016, 2(Suppl 1):8 DOI 10.1186/s40810-016-0021-4 MEETINGABSTRACTS Open Access 19th biennial IPEG Meeting Nijmegen, The Netherlands. 26-30 October 2016 Published: 29 November 2016 Training course measures. This will be illustrated by means of pertinent examples. These include elucidating the mechanisms of stimulant action re- A1 mediating deficient impulse control and the role of the cannabinoid Thalamocortical sleep oscillations system in human working memory, as well as drug effects on Igor Timofeev1,2 sensory gating and specific aspects of visual-spatial attention. Other 1Department of Psychiatry and Neuroscience, Université Laval, Québec, examples concern the added sensitivity of EEG and ERP measures, Canada; 2Centre de recherche de l’Institut universitaire en santé mentale relative to that of performance measures, in detecting effects of alco- de Québec (CRIUSMQ), Université Laval, Québec, Canada hol, and more generally in monitoring and predicting vigilance and Neuropsychiatric Electrophysiology 2016, 2(Suppl 1):A1 the ability to detect external signals in the immediate future. Rela- tions between brain signals and cognitive competences are revealed In waking and sleeping states, thalamocortical system generates a by either comparing different individuals, or moment-to-moment variety of oscillations ranging from 0.1 Hz to hundreds of Hz. Most of fluctuations within individuals, or differences in state (e.g., drug- them are present during NREM sleep, but slower activities prevail in induced) within individuals. this state of vigilance. Thalamocortical network is organized in a loop in which thalamocortical cells excite reticular thalamic and neocor- tical cells, reticular thalamic cells inhibit thalamocortical cells and A3 corticothalamic cells excite thalamocortical and reticular thalamic EEG and ERP as key techniques for functional brain alterations cells.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • Enhanced Dendritic Inhibition and Impaired NMDAR Activation in a Mouse Model of Down Syndrome
    This Accepted Manuscript has not been copyedited and formatted. The final version may differ from this version. Research Articles: Neurobiology of Disease Enhanced dendritic inhibition and impaired NMDAR activation in a mouse model of Down syndrome Jan M. Schulz1, Frederic Knoflach2, Maria-Clemencia Hernandez2 and Josef Bischofberger1 1Department of Biomedicine, University of Basel, Pestalozzistr. 20, CH-4056 Basel, Switzerland 2Pharma Research and Early Development, Discovery Neuroscience Department, F. Hoffmann-La Roche Ltd, Basel, Switzerland https://doi.org/10.1523/JNEUROSCI.2723-18.2019 Received: 22 October 2018 Revised: 9 April 2019 Accepted: 10 April 2019 Published: 18 April 2019 Author contributions: J.M.S., M.C.H., and J.B. designed research; J.M.S. and F.K. performed research; J.M.S. analyzed data; J.M.S. and J.B. wrote the first draft of the paper; J.M.S. and J.B. wrote the paper; F.K., M.C.H., and J.B. edited the paper. Conflict of Interest: The authors declare no competing financial interests. We would like to thank Tom Otis for helpful comments on the manuscript. We thank Selma Becherer and Martine Schwager for mouse genotyping, histochemical stainings and technical assistance, Marie-Claire Pflimlin for some electrophysiological recordings and Andrew Thomas for RO4938581 supply. This work was supported by a Roche Postdoctoral Fellowship and by the Swiss National Science Foundation (SNSF, Project 31003A_176321). The authors declare no competing financial interests. Correspondence: Dr. Josef Bischofberger, Department of Biomedicine, University of Basel, Pestalozzistr. 20, CH-4046 Basel, Switzerland, Phone: +41-61-2672729, E-mail: [email protected] Cite as: J.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Lääkeaineiden Yleisnimet (INN-Nimet) 21.6.2021
    Lääkealan turvallisuus- ja kehittämiskeskus Säkerhets- och utvecklingscentret för läkemedelsområdet Finnish Medicines Agency Lääkeaineiden yleisnimet (INN-nimet) 21.6.
    [Show full text]
  • World of Cognitive Enhancers
    ORIGINAL RESEARCH published: 11 September 2020 doi: 10.3389/fpsyt.2020.546796 The Psychonauts’ World of Cognitive Enhancers Flavia Napoletano 1,2, Fabrizio Schifano 2*, John Martin Corkery 2, Amira Guirguis 2,3, Davide Arillotta 2,4, Caroline Zangani 2,5 and Alessandro Vento 6,7,8 1 Department of Mental Health, Homerton University Hospital, East London Foundation Trust, London, United Kingdom, 2 Psychopharmacology, Drug Misuse, and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom, 3 Swansea University Medical School, Institute of Life Sciences 2, Swansea University, Swansea, United Kingdom, 4 Psychiatry Unit, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy, 5 Department of Health Sciences, University of Milan, Milan, Italy, 6 Department of Mental Health, Addictions’ Observatory (ODDPSS), Rome, Italy, 7 Department of Mental Health, Guglielmo Marconi” University, Rome, Italy, 8 Department of Mental Health, ASL Roma 2, Rome, Italy Background: There is growing availability of novel psychoactive substances (NPS), including cognitive enhancers (CEs) which can be used in the treatment of certain mental health disorders. While treating cognitive deficit symptoms in neuropsychiatric or neurodegenerative disorders using CEs might have significant benefits for patients, the increasing recreational use of these substances by healthy individuals raises many clinical, medico-legal, and ethical issues. Moreover, it has become very challenging for clinicians to Edited by: keep up-to-date with CEs currently available as comprehensive official lists do not exist. Simona Pichini, Methods: Using a web crawler (NPSfinder®), the present study aimed at assessing National Institute of Health (ISS), Italy Reviewed by: psychonaut fora/platforms to better understand the online situation regarding CEs.
    [Show full text]
  • Comparing the Effects of Α5gabaa Receptor Negative Allosteric Modulators on Inhibitory Currents in Hippocampal Neurons
    Comparing the Effects of α5GABAA Receptor Negative Allosteric Modulators on Inhibitory Currents in Hippocampal Neurons by Marc Anthony Manzo A thesis submitted in conformity with the requirements for the degree of Master of Science Department of Physiology University of Toronto © Copyright by Marc Anthony Manzo 2020 Comparing the effects of α5GABAA receptor negative allosteric modulators on inhibitory currents in hippocampal neurons Marc Anthony Manzo Master of Science Department of Physiology University of Toronto 2020 Abstract Overactivity of α5 subunit-containing GABAA (α5GABAA) receptors contributes to cognitive deficits in many neurological disorders. Negative allosteric modulators that preferentially inhibit α5GABAA receptors (α5-NAMs) have been developed to treat such deficits. α5-NAMs have been primarily studied using recombinant GABAA receptors expressed in non-neuronal cells. Surprisingly, although the native neuronal environment influences GABAA receptor pharmacology, no study has directly compared α5-NAM effects on GABAA receptors expressed in primary neurons. This comparison would aid in the development and selection of more effective compounds for clinical trials. Thus, the current study was undertaken to compare the effects of five α5-NAMs on the function of GABAA receptors in cultured mouse hippocampal neurons, using whole-cell voltage- clamp recordings. While α5-NAMs similarly inhibited GABAA receptor-mediated currents; the most efficacious concentrations varied 100-fold. Given that maximal efficacy is similar ii among α5-NAMs, factors such as potency, selectivity, and toxicity should be emphasized in the development and selection of α5-NAMs for clinical trials. iii Acknowledgments Over the last two years, I have grown tremendously as both a person and scientist. This growth was a consequence of the talented people I worked with and learned from on a daily basis.
    [Show full text]
  • Paving the Way for Therapy
    Paving the Way for Therapy 2nd International Conference of the Trisomy 21 Research Society June 7-11, 2017 Feinberg Conference Center, Northwestern Memorial Hospital Chicago, IL USA Founding Sponsors of T21RS 1 Paving the Way for Therapy 2nd International Conference of the Trisomy 21 Research Society June 7-11, 2017 Feinberg Conference Center, Northwestern Memorial Hospital Chicago, IL USA Conference Organizers Roger Reeves, PhD Mara Dierssen, MD, PhD Johns Hopkins University School of CRG – Center for Genomic Medicine Regulation Jean Delabar, PhD John O’Bryan, PhD CNRS-ICM University of Illinois Chicago Scientific Program Committee Mara Dierssen, MD, PhD - Chair Anita Bhattacharyya, PhD CRG-Center for Genomic Regulation University of Wisconsin-Madison Cynthia Lemere, PhD Jean Delabar, PhD Harvard Medical School CNRS-ICM Dean Nizetic, MD, PhD Jorge Busciglio, PhD Nanyang Technological University University of California-Irvine Singapore Nicole Schupf, PhD, DrPH Pablo Caviedes, MD, PhD Columbia University Medical Center University of Chile Deny Menghini, PhD Bambino Gesu Children's Hospital 2 3 Annette Karmiloff-Smith Thesis Award Program COMPETITION FOR OUTSTANDING PH.D. THESIS Application Deadline: June 30, 2018 Prizes will be awarded for up to 2 outstanding doctoral dissertations. Each recipient will receive an honorarium of 1,000 Euros. The topic of the dissertation must be in the field of Down syndrome Eligibility Participation in the 2017 competition is limited to candidates who obtained the Ph.D. title during the period January 1, 2016-December 31, 2017. Applicants must be members of T21RS (www.t21rs.org/register). Required Documentation Documentation accompanying the application must be submitted exclusively in an email to [email protected] in PDF format and must be written in English.
    [Show full text]
  • GABA Receptor Gamma-Aminobutyric Acid Receptor; Γ-Aminobutyric Acid Receptor
    GABA Receptor Gamma-aminobutyric acid Receptor; γ-Aminobutyric acid Receptor GABA receptors are a class of receptors that respond to the neurotransmitter gamma-aminobutyric acid (GABA), the chief inhibitory neurotransmitter in the vertebrate central nervous system. There are two classes of GABA receptors: GABAA and GABAB. GABAA receptors are ligand-gated ion channels (also known as ionotropic receptors), whereas GABAB receptors are G protein-coupled receptors (also known asmetabotropic receptors). It has long been recognized that the fast response of neurons to GABA that is blocked by bicuculline and picrotoxin is due to direct activation of an anion channel. This channel was subsequently termed the GABAA receptor. Fast-responding GABA receptors are members of family of Cys-loop ligand-gated ion channels. A slow response to GABA is mediated by GABAB receptors, originally defined on the basis of pharmacological properties. www.MedChemExpress.com 1 GABA Receptor Agonists, Antagonists, Inhibitors, Activators & Modulators (+)-Bicuculline (+)-Kavain (d-Bicuculline) Cat. No.: HY-N0219 Cat. No.: HY-B1671 (+)-Bicuculline is a light-sensitive competitive (+)-Kavain, a main kavalactone extracted from Piper antagonist of GABA-A receptor. methysticum, has anticonvulsive properties, attenuating vascular smooth muscle contraction through interactions with voltage-dependent Na+ and Ca2+ channels. Purity: 99.97% Purity: 99.98% Clinical Data: No Development Reported Clinical Data: Launched Size: 10 mM × 1 mL, 50 mg, 100 mg Size: 10 mM × 1 mL, 5 mg, 10 mg (-)-Bicuculline methobromide (-)-Bicuculline methochloride (l-Bicuculline methobromide) Cat. No.: HY-100783 (l-Bicuculline methochloride) Cat. No.: HY-100783A (-)-Bicuculline methobromide (l-Bicuculline (-)-Bicuculline methochloride (l-Bicuculline methobromide) is a potent GABAA receptor methochloride) is a potent GABAA receptor antagonist.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • Subtype Selective Γ-Aminobutyric Acid Type a Receptor (GABAAR) Modulators Acting at the Benzodiazepine Binding Site: an Update
    Subtype selective γ-Aminobutyric Acid Type A Receptor (GABAAR) Modulators Acting at the Benzodiazepine Binding Site: An Update Samuele Maramaia,*, Mohamed Benchekrouna,b, Simon E. Wardc, John R. Atack c. a Sussex Drug Discovery Centre, University of Sussex, Brighton, BN1 9QJ (UK) b Conservatoire National des Arts et Métiers, Équipe de Chimie Moléculaire, Laboratoire de Génomique Bioinformatique et Chimie Moléculaire, GBCM, EA7528, 2 rue Conté 75003 Paris (FR). c Medicines Discovery Institute, Cardiff University, Main Building, Park Place, Cardiff, CF10 3AT (UK) *Corresponding author: [email protected], Phone +44 (0)1273 876659 Abstract γ-Aminobutyric acid (GABA) is the major inhibitory neurotransmitter within the central nervous system (CNS) with fast, trans-synaptic and modulatory extrasynaptic effects being mediated by the ionotropic GABA Type A receptors (GABAARs). These receptors are of particular interest since they are the molecular target of a number of pharmacological agents, of which the benzodiazepines (BZDs), such as diazepam, are the best described. The anxiolytic, sedating and myorelaxant effects of BZDs are mediated by separate populations of GABAARs containing either α1, α2, α3 or α5 subunits and the molecular dissection of the pharmacology of BZDs indicates that subtype-selective GABAAR modulators will have novel pharmacological profiles. This is best exemplified by α2/α3-GABAAR positive allosteric modulators (PAMs) and α5-GABAAR negative allosteric modulators (NAMs), which were originally developed as non-sedating anxiolytics and cognition enhancers, respectively. This review aims to summarize the current state of the field of subtype-selective GABAAR modulators acting via the BZD binding site and their potential clinical indications. 1.
    [Show full text]